IL255591B - Gemcitabine-[phenyl-benzoxy-l-alaninyl]-phosphate (nuc-1031) for use as a neoadjuvant or adjuvant in cancer treatments - Google Patents

Gemcitabine-[phenyl-benzoxy-l-alaninyl]-phosphate (nuc-1031) for use as a neoadjuvant or adjuvant in cancer treatments

Info

Publication number
IL255591B
IL255591B IL255591A IL25559117A IL255591B IL 255591 B IL255591 B IL 255591B IL 255591 A IL255591 A IL 255591A IL 25559117 A IL25559117 A IL 25559117A IL 255591 B IL255591 B IL 255591B
Authority
IL
Israel
Prior art keywords
benzoxy
nuc
gemcitabine
alanine
adjuvant
Prior art date
Application number
IL255591A
Other languages
English (en)
Hebrew (he)
Other versions
IL255591A (en
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL255591(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NuCana plc filed Critical NuCana plc
Publication of IL255591A publication Critical patent/IL255591A/en
Publication of IL255591B publication Critical patent/IL255591B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL255591A 2015-05-14 2017-11-12 Gemcitabine-[phenyl-benzoxy-l-alaninyl]-phosphate (nuc-1031) for use as a neoadjuvant or adjuvant in cancer treatments IL255591B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (2)

Publication Number Publication Date
IL255591A IL255591A (en) 2018-01-31
IL255591B true IL255591B (en) 2021-10-31

Family

ID=53276184

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255591A IL255591B (en) 2015-05-14 2017-11-12 Gemcitabine-[phenyl-benzoxy-l-alaninyl]-phosphate (nuc-1031) for use as a neoadjuvant or adjuvant in cancer treatments

Country Status (26)

Country Link
US (3) US20180289733A1 (enExample)
EP (2) EP3197456B2 (enExample)
JP (1) JP6761852B2 (enExample)
KR (1) KR20180021697A (enExample)
CN (2) CN107835687A (enExample)
AU (2) AU2015394135B2 (enExample)
BR (1) BR112017024461B1 (enExample)
CA (1) CA2985540C (enExample)
CY (1) CY1120516T1 (enExample)
DK (1) DK3197456T3 (enExample)
EA (1) EA201792509A1 (enExample)
ES (1) ES2668377T3 (enExample)
HR (1) HRP20180762T1 (enExample)
HU (1) HUE038541T2 (enExample)
IL (1) IL255591B (enExample)
LT (1) LT3197456T (enExample)
MX (2) MX390506B (enExample)
MY (1) MY192081A (enExample)
PH (1) PH12017502086B1 (enExample)
PL (1) PL3197456T3 (enExample)
PT (1) PT3197456T (enExample)
RS (1) RS57371B1 (enExample)
SI (1) SI3197456T1 (enExample)
SM (1) SMT201800303T1 (enExample)
TR (1) TR201806642T4 (enExample)
WO (1) WO2016181093A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
EP3353201B1 (en) 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
CA3007347C (en) 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SI3393478T1 (sl) * 2015-12-23 2020-07-31 NuCana plc Kombinacijska terapija
KR102566461B1 (ko) * 2015-12-23 2023-08-14 뉴카나 피엘씨 조합 요법
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
EP3863674A2 (en) * 2018-10-12 2021-08-18 The Regents of the University of Colorado, a body corporate Compositions and methods for reducing cancer stem cells
CN114533739B (zh) * 2021-01-31 2023-12-29 兰州大学 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GHAZALY E ET AL., " ACELARIN: A NOVEL NUCLEOTIDE ANALOGUE THAT OVERCOMES THE KEY CANCER RESISTANCE MECHANISMS ASSOCIATED WITH POOR SURVIVAL", 31 December 2014 (2014-12-31) *
GHAZALY E ET AL., " PROGEM1: A PHASE I/II STUDY OF A FIRST-IN-CLASS NUCLEOTIDE ANALOGUE ACELARIN (NUC-1031) IN PATIENTS WITH ADVANCED SOLID TUMORS", 31 December 2014 (2014-12-31) *
JIMENO A ET AL., A DIRECT PANCREATIC CANCER XENOGRAFT MODEL AS A PLATFORM FOR CANCER STEM CELL THERAPEUTIC DEVELOPMENT, 27 January 2009 (2009-01-27) *
LI Y ET AL., " PANCREATIC CANCER STEM CELLS: EMERGING TARGET FOR DESIGNING NOVEL THERAPY", 20 March 2012 (2012-03-20) *
MACS MILTENYI BIOTEC, " CANCER STEM CELLS", 31 December 2008 (2008-12-31) *
MCGUIGAN C ET AL., " A PHOSPHORAMIDATE PROTIDE (NUC-1031) AND ACQUIRED AND INTRINSIC RESISTANCE TO GEMCITABINE", 31 December 2011 (2011-12-31) *
SHE M ET AL., " RESISTANCE OF LEUKEMIC STEM-LIKE CELLS IN AML CELL LINE KG1A TO NATURAL KILLER CELL-MEDIATED CYTOTOXICITY", 21 December 2011 (2011-12-21) *
SLUSARCZYK M ET AL., " APPLICATION OF PROTIDE TECHNOLOGY TO GEMCITABINE: A SUCCESSFUL APPROACH TO OVERCOME THE KEY CANCER RESISTANCE MECHANISMS LEADS TO A NEW AGENT (NUC-1031) IN CLINICAL DEVELOPMENT", 14 February 2014 (2014-02-14) *

Also Published As

Publication number Publication date
JP2018515618A (ja) 2018-06-14
AU2015394135B2 (en) 2021-09-16
US20230226092A1 (en) 2023-07-20
CN107835687A (zh) 2018-03-23
EP3415149A1 (en) 2018-12-19
MX374946B (es) 2025-03-06
KR20180021697A (ko) 2018-03-05
BR112017024461A2 (pt) 2018-07-24
CA2985540A1 (en) 2016-11-17
CY1120516T1 (el) 2019-07-10
HUE038541T2 (hu) 2018-10-29
CN115837028A (zh) 2023-03-24
PT3197456T (pt) 2018-05-22
MX2017014544A (es) 2018-09-26
JP6761852B2 (ja) 2020-09-30
US20210100825A1 (en) 2021-04-08
RS57371B1 (sr) 2018-08-31
BR112017024461B1 (pt) 2023-04-04
LT3197456T (lt) 2018-07-10
EP3197456A1 (en) 2017-08-02
MX2020009154A (es) 2022-03-08
AU2015394135A1 (en) 2017-12-14
EA201792509A1 (ru) 2018-05-31
DK3197456T3 (en) 2018-06-06
IL255591A (en) 2018-01-31
US20180289733A1 (en) 2018-10-11
WO2016181093A1 (en) 2016-11-17
PL3197456T3 (pl) 2018-09-28
EP3197456B2 (en) 2023-10-11
CA2985540C (en) 2021-08-24
SMT201800303T1 (it) 2018-07-17
HRP20180762T1 (hr) 2018-08-24
ES2668377T3 (es) 2018-05-17
EP3197456B1 (en) 2018-04-04
PH12017502086A1 (en) 2018-04-30
MX390506B (es) 2025-03-20
PH12017502086B1 (en) 2022-12-09
AU2021277614A1 (en) 2021-12-23
TR201806642T4 (tr) 2018-06-21
SI3197456T1 (en) 2018-08-31
MY192081A (en) 2022-07-26

Similar Documents

Publication Publication Date Title
IL255261A0 (en) Methods for treating cancer
IL284875A (en) Lasofoxifene treatment of breast cancer
HUE059694T2 (hu) Készítmény rák kezelésére
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
ZA201803742B (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
IL258684A (en) Combination therapy for treating malignancies
HUE049072T2 (hu) AXL-specifikus ellenanyag-drog konjugátumok rák kezelésére
PL3197456T3 (pl) Leczenie nowotworów
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
IL259996A (en) Combinations for cancer treatment
EP3302097A4 (en) Heat treatment to produce glycosides
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL265751B (en) Immunogenic compounds for cancer therapy
EP3012292A4 (en) PROCESSING AGENTS AND COMPOSITION
HUE055132T2 (hu) Virulenciában gyengített baktériumok rosszindulatú szolid tumorok kezelésére
DK3294769T3 (da) Behandling for multipelt myelom (mm)
ZA201707024B (en) Cancer treatment composition
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
EP3305975A4 (en) Clothing treatment device
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL260814A (en) Cancer treatment
GB201522433D0 (en) Cancer treatment
DK3277325T3 (da) Kombinationsimmunterapi for cancer
EP3296455A4 (en) Clothing treatment apparatus
EP3295964A4 (en) Clothing treatment apparatus: